# Artelo Biosciences Advances Cannabinoid-Based Glaucoma Treatments > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-based-glaucoma-treatments-emerging-study/ > **Published:** 2026-03-25T21:31:21-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:39:25-04:00 > **Clinical Summary:** Explore cannabinoid-based glaucoma treatments targeting intraocular pressure reduction in a fully funded clinical study advancing new therapeutic options. --- ✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchNeurologyIndustry Why This Matters Clinicians managing glaucoma patients need to understand that cannabinoid-based treatments targeting endocannabinoid signaling represent a mechanistically distinct approach to intraocular pressure reduction that could offer alternatives for patients who fail or cannot tolerate conventional therapies. This expansion signals increasing clinical validation of cannabis-derived compounds for serious ocular conditions, which should inform ophthalmologists’ patient counseling about emerging evidence-based options beyond traditional prostaglandin analogs and beta-blockers. For patients with refractory glaucoma, access to fully funded [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) in this space means potential enrollment opportunities in rigorously controlled studies that could determine safety and efficacy in ways that current anecdotal cannabis use cannot Clinical Summary Artelo Biosciences is advancing cannabinoid-based therapeutics into the glaucoma market, which represents a 16.3 billion dollar opportunity, through a fully funded clinical study focused on modulating endocannabinoid and lipid-signaling pathways. The company’s mechanistic approach targets intraocular pressure reduction and neuroprotection, two critical pathways in glaucoma pathogenesis where cannabinoid receptor modulation may offer therapeutic benefit beyond current standard-of-care options. This development reflects growing clinical interest in cannabis-derived compounds for conditions like glaucoma where conventional treatments have limitations or tolerability issues. For clinicians, this signals potential future expansion of cannabinoid-based treatment options in ophthalmology and reinforces the importance of staying informed about emerging [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) evidence in specialty fields. Patients with glaucoma should be aware that cannabinoid therapies are under investigation as adjunctive or [alternative treatments](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/), though they remain investigational and should not replace proven therapies outside of clinical trial settings. Dr. Caplan’s Take “When a company like Artelo pursues glaucoma through endocannabinoid lipid signaling rather than just cannabinoid receptor activation, they’re finally asking the right mechanistic question, and that’s what separates legitimate [drug development](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/) from cannabis marketing. The [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) regulates intraocular pressure through pathways we’re only beginning to understand clinically, so a rigorous, fully funded study could generate evidence we desperately need instead of the anecdotal reports that currently dominate patient conversations. If this works, it changes how we think about neuroprotection in glaucoma, but until we see the data, I tell my patients we’re watching science unfold, not Clinical Perspective While Artelo’s foray into glaucoma treatment via endocannabinoid system modulation represents an intriguing mechanistic approach, clinicians should recognize that translating basic lipid-signaling research into approved therapeutics involves substantial scientific and regulatory uncertainty. The endocannabinoid system’s role in intraocular pressure regulation has theoretical support, but clinical efficacy and safety data in human glaucoma populations remain limited, and cannabinoid-based therapies have faced variable success in other disease domains due to off-target effects and individual variability in response. Key confounders include the heterogeneity of glaucoma phenotypes, potential interactions with concurrent glaucoma medications, and the still-evolving regulatory framework for cannabis-derived pharmaceuticals. Until phase 3 data are available and independent clinical trials demonstrate meaningful advantages over existing agents, glaucoma management should continue following established guidelines using prostaglandin 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Artelo+Biosciences+Expansion+into+%2416.3B+Glaucoma+Market%2C+Via+Fully+Funded+Study+...+%40drcaplan&url=https%3A%2F%2Fwww.theglobeandmail.com%2Finvesting%2Fmarkets%2Fmarkets-news%2FGlobeNewswire%2F940364%2Fartelo-biosciences-expansion-into-16-3b-glaucoma-market-via-fully-funded-study-highlights-multi-platform-pipeline-strength%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.theglobeandmail.com%2Finvesting%2Fmarkets%2Fmarkets-news%2FGlobeNewswire%2F940364%2Fartelo-biosciences-expansion-into-16-3b-glaucoma-market-via-fully-funded-study-highlights-multi-platform-pipeline-strength%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Artelo+Biosciences+Expansion+into+%2416.3B+Glaucoma+Market%2C+Via+Fully+Funded+Study+...+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.theglobeandmail.com%2Finvesting%2Fmarkets%2Fmarkets-news%2FGlobeNewswire%2F940364%2Fartelo-biosciences-expansion-into-16-3b-glaucoma-market-via-fully-funded-study-highlights-multi-platform-pipeline-strength%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [Artelo Biosciences Expands into Glaucoma Market with New Study – Intellectia AI](https://cedclinic.com/artelo-biosciences-glaucoma-study-cannabinoid-research/) 📰 Source: [https://www.theglobeandmail.com/investing/markets/markets-news/GlobeNewswire/940364/artelo-biosciences-expansion-into-16-3b-glaucoma-market-via-fully-funded-study-highlights-multi-platform-pipeline-strength/](https://www.theglobeandmail.com/investing/markets/markets-news/GlobeNewswire/940364/artelo-biosciences-expansion-into-16-3b-glaucoma-market-via-fully-funded-study-highlights-multi-platform-pipeline-strength/) Further Reading Research Digest[Research Digest: 5 Recent Studies – March 25, 2026](https://cedclinic.com/research-digest-recent-studies-march-2026/) Evidence WatchChildhood Adversity Linked to Nearly Doubled Odds of Heart Attack in Adulthood CED Clinic Blog[Certificates of analysis, how patients can read between the lines #4](https://cedclinic.com/certificate-of-analysis-cannabis-safety/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Artelo expands into glaucoma with funded study – ARTL – Stock Titan](https://cedclinic.com/cb2-receptor-targeting-glaucoma-study-artelo-expands/) An overview of Artelo Biosciences' strategic expansion into the glaucoma market through a fully funded clinical study. [Read More](https://cedclinic.com/cb2-receptor-targeting-glaucoma-study-artelo-expands/) The Science Behind Cannabis and Its Therapeutic Benefits – NUG Magazine Explore the scientific foundations of cannabis-derived therapies and their potential applications in medical treatment. Explore Science [Q&A: What does science say about plants as medicine?](https://cedclinic.com/qa-what-does-science-say-about-plants-as-medicine/) A detailed Q&A addressing the scientific evidence supporting plant-based medicines including cannabinoids. [Learn More](https://cedclinic.com/qa-what-does-science-say-about-plants-as-medicine/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).